Status:
TERMINATED
High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department
Lead Sponsor:
Hennepin Healthcare Research Institute
Conditions:
Abdominal Pain
Renal Colic
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
Intravenous lidocaine will be given at a dose of 2 mg/kg intravenously to patients in the emergency department with a diagnosis of acute abdominal pain. Its efficacy will be compared to 1 mg of intrav...
Detailed Description
Abdominal pain is a common chief complaint for patients presenting to the emergency department (ED) in the United States. Intravenous opioids are commonly used to treat acute abdominal pain in the ED....
Eligibility Criteria
Inclusion
- Must be a patient in the emergency department (ED)
- Must have acute abdominal pain, defined as abdominal or flank pain of a duration of 7 days or less
- Predicted treatment must include the use of an intravenous opiate
Exclusion
- Cardiac conduction system impairment (QTc duration \> 0.5s, QRS duration \> 0.12s, PR interval \<0.12s or \> 0.2s)
- Known renal (CKD \>2) or liver disease (Childs-Pugh B or greater)
- Hemodynamically instability, defined by the attending physician
- Pregnant or breastfeeding
- Have a known allergy to either medication
- Used of prescription or illicit opioids within the previous week
- Patients with a chronic pain disorder, defined as use of any analgesic medication on more days than not during the four weeks preceding the acute episode of pain
Key Trial Info
Start Date :
February 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT04398316
Start Date
February 18 2021
End Date
June 30 2021
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415